Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Date:5/31/2008

-- IFM presents updated results from Phase III clinical trial --

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and dexamethasone (VcD) to vincristine, adriamycin and dexamethasone (VAD). Results showed high complete remission (CR) rates of 19 percent in the VcD arm as induction therapy and 35 percent post-transplantation. These high CR rates contributed to 141 patients not requiring a second transplant. In addition, data showed 95 percent of patients in the VcD arm were alive at one year. The study was conducted by the Intergroupe Francophone du Myelome (IFM) cooperative group and Nantes University Hospital (France) and selected for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 30 - June 3, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"These updated results clearly confirm that the high CR rates with induction therapy improved post-transplantation outcomes, including a decrease in the need for second transplantation," said Professor Harousseau, M.D., Hotel-Dieu Hospital. "We also are encouraged by the promising survival data already seen to date. This VELCADE based therapy now could be considered the standard induction treatment pre-transplant to which other regimens, including novel agents, should be studied against."

VELCADE is under priority review with the Food and Drug Administration (FDA) for potential approval in newly diagnosed multiple myeloma. The PDUFA date is June 20, 2008. VELCADE is the market leader in relapsed multiple myeloma and mantle cell lymphoma (MCL).

"These data, as well as the results from multiple clinical trials continue to demonstrate the abili
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
3. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
4. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Nov. 25 The FDA granted traditiona...s, a non-nucleoside reverse transcriptase inhibito...y indicated for use in treatment-experienced adult...1 strains resistant to an NNRTI and other antiretr...based on 48-week data from two Phase 3 studies kno...
(Date:11/25/2009)...lif., Nov. 25 AMPAC Fine Chemicals...ration (Nasdaq: APFC ) announced today that it re...nability Award at the Annual Statewide Environment...rs and Technology Association (CMTA), the Industri...l Industry Council of California (CICC) held in Sa...
(Date:11/25/2009)...v. 25 Reportlinker.com announces t...ts catalogue: ,, United States Dental Devices ...://www.reportlinker.com/p0158733/United-States-Den...html ,, United States Dental Devices Market An... This report is an essential source for in-depth i...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Cardica Receives NASDAQ Notification of Non Compliance 13866 1Cardica Receives NASDAQ Notification of Non Compliance 13866 2Exercise May Help Maintain Weight Loss 56302 1Exercise May Help Maintain Weight Loss 56302 2Pharmacists Urge the Public to Begin Getting Immunized 56298 1Pharmacists Urge the Public to Begin Getting Immunized 56298 2Pharmacists Urge the Public to Begin Getting Immunized 56298 3
(Date:11/26/2009)...wire/ -- The diabetes population in the United Sta...annual medical spending on the disease is projecte... according to a study published in the December is...abetes ® Program (NCDP), a program of Novo No...e University of Chicago. ,, According to the fo...
(Date:11/26/2009)...o strains or worse , , THURSDAY, Nov. 26...th stuffing your turkey full to bursting, but you ...case as you pack for holiday trips. , More than...al emergency rooms, doctors, offices, clinics and ...ies, such as muscle strains, pulls and tears, acco...
(Date:11/26/2009)... Live Life Again Center, a practice offering weig...mber of physicians who are taking advantage of po...viduals who are interested in surgical weight loss...lizing Facebook to share before-and-after photos a...ty. , Dallas, TX (Vocus) ...
(Date:11/26/2009)....A. is offering free nationwide confidential consu... pills who have suffered a Deep Vein Thrombosis (D...ther related cardiac issues or had their Gallbladd...6405 or go to the firm’s website at http://...uation form. , (PRWEB) No...
(Date:11/25/2009)...ewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.... will host two investor events in December: ,, ...a.m. CT/10:00 a.m. ET ,, Principal investigat...rfilzomib in relapsed and/or refractory multiple m...f Hematology (ASH) Annual Meeting and Exposition i...
Breaking Medicine News(10 mins):Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...ser Comments on President Obama,s Town Hall Acknow...QUERQUE, N.M., May 15 Cody Unser, a 22-year-o... the Cody Unser First Step Foundation, commends Pr...for rapid acceleration of stem cell research so th...
...study techniques identify anti-inflammatory compon...Day News) -- Ginseng has been used in medicine for...ealth is expanding: A new study has found that the...even constituents of ginseng, called ginsenosides,...
..., May 15 The American Association of Clinical End...ology (AACE and ACE) today released a Position Sta...osition is a strong statement in support of contin...b ) , , The statement, shown below in its entiret...
...ecognized as the Most Effective Room Air Purifier ...., May 15 /PRNewswire/ -- IQAir North America, I...ture of superior air cleaning products, announced ...ests conducted by actual parents, the HealthPro Pl...
...O (May 15, 2009)Fox Chase Cancer Center researcher...ted with an earlier onset of prostate cancer in Ca...cancer. If the data are confirmed, the marker may ...rogram at Fox Chase, will present the data at the ...
...ny years, it has been known that aspirin is benefi...heart attacks. But which of the many different typ...up of researchers led by Dr. Sean Nordt from the U...egular aspirin chewed and swallowed, and chewable ...
Other Medicine News:Health News:Disability Activist Urges Obama to Escalate Stem Cell Research to End Paralysis For Millions of Americans 2Health News:New Discovery Shows Ancient Herb Fights Inflammation 2Health News:Major Physician Group Issues Statement in Support of Physician/Industry Relationships 2Health News:Major Physician Group Issues Statement in Support of Physician/Industry Relationships 3Health News:IQAir HealthPro Plus Wins Parent Tested Parent Approved Seal of Approval Award 2Health News:IQAir HealthPro Plus Wins Parent Tested Parent Approved Seal of Approval Award 3Health News:IQAir HealthPro Plus Wins Parent Tested Parent Approved Seal of Approval Award 4Health News:Genetic marker may predict early onset of prostate cancer 2
...IP joint or DIP joint flexion following injury or ...n comfort and softness, the breathable, foam-lined...allows for infinite adjustments to restore motion....FoamWrap™ splints are made with fabrifoam&re...
...y and control motion for persons with arthritis, a...due to stroke or cerebral palsy. Oval-8 splints ar... broad bands to comfortably distribute pressure. T...satile ring splint available. Whether using Oval-8...
Bariatric Knee Immobilizer
...nient, reusable, patient-friendly and effective al...opedic conditions/instabilities. These products ar...d lateral to medial influence of cutaneous nerve r...sue structures. Maximum benefit is accomplished by...
Medicine Products: